We are live on ! Find out more
ARCT icon

Arcturus Therapeutics
ARCT

31 hedge funds and large institutions have $60.3M invested in Arcturus Therapeutics in 2014 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 11 increasing their positions, 6 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

233% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 3

83% more repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 6

29% more funds holding

Funds holding: 24 → 31 (+7)

0% more capital invested

Capital invested by funds: $60.2M → $60.3M (+$30.7K)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

29% less call options, than puts

Call options by funds: $1.81M | Put options by funds: $2.54M

Holders
31
Holders Change
+7
Holders Change %
+29.17%
% of All Funds
0.89%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.06%
New
10
Increased
11
Reduced
6
Closed
3
Calls
$1.81M
Puts
$2.54M
Net Calls
-$729K
Net Calls Change
-$729K

Top Buyers

1
JGC
J. Goldman & Co
New York
+$2.26M
2
DCM
DAFNA Capital Management
California
+$1.3M
3
Morgan Stanley
Morgan Stanley
New York
+$1.13M
4
GPCM
Granite Point Capital Management
Massachusetts
+$1.03M
5
GPP
Great Point Partners
Connecticut
+$678K

Top Sellers

1
Verition Fund Management
Verition Fund Management
Connecticut
-$3.44M
2
ACPU
Arrowgrass Capital Partners (US)
Delaware
-$1.56M
3
SIM
Spark Investment Management
New York
-$487K
4
EEG
E.E. Geduld
-$172K
5
PCM
Prelude Capital Management
New York
-$94.8K
Name Holding Trade Value Shares
Change 		Change in
Stake
JP Morgan Chase
1
JP Morgan Chase
New York
$14.3M +$331K +2,739 +2%
KCM
2
Knoll Capital Management
Florida
$11.9M – – –
AWMDMG
3
Austin W. Marxe & David M. Greenhouse
New York
$10.4M – – –
GPP
4
Great Point Partners
Connecticut
$5.76M +$678K +5,614 +13%
SC
5
Sophrosyne Capital
New York
$5.25M +$523K +4,331 +11%
JGC
6
J. Goldman & Co
New York
$2.27M +$2.26M +18,750 New
Verition Fund Management
7
Verition Fund Management
Connecticut
$1.92M -$3.44M -28,513 -64%
Morgan Stanley
8
Morgan Stanley
New York
$1.69M +$1.13M +9,343 +204%
DCM
9
DAFNA Capital Management
California
$1.47M +$1.3M +10,768 +784%
GPCM
10
Granite Point Capital Management
Massachusetts
$1.04M +$1.03M +8,571 New
TMC
11
Trellus Management Company
Florida
$955K +$117K +970 +14%
B
12
Bailard
California
$606K – – –
GIP
13
Granite Investment Partners
California
$322K +$4.59K +38 +1%
ST
14
Spot Trading
Illinois
$318K +$316K +2,621 New
GGHC
15
Gilder Gagnon Howe & Co
New York
$308K +$307K +2,544 New
Goldman Sachs
16
Goldman Sachs
New York
$281K +$280K +2,322 New
Millennium Management
17
Millennium Management
New York
$276K -$77.5K -642 -22%
BAAM
18
Baker Avenue Asset Management
California
$263K -$77.6K -643 -23%
EEG
19
E.E. Geduld
$260K -$172K -1,428 -40%
CS
20
Credit Suisse
Switzerland
$226K +$26.6K +220 +13%
VanEck Associates
21
VanEck Associates
New York
$93K +$18.6K +154 +25%
ACM
22
Atika Capital Management
New York
$87K +$86.2K +714 New
US Bancorp
23
US Bancorp
Minnesota
$62K +$61.3K +508 New
Bank of America
24
Bank of America
North Carolina
$59K +$43.1K +357 +277%
PCM
25
Prelude Capital Management
New York
$47K -$94.8K -785 -67%
1
2

ARCT Hedge Fund Activity: Q2 2014 in Review

31 of the 3,479 institutional investors tracked by Wall St. Rank reported a position in Arcturus Therapeutics (ARCT) for Q2 2014, worth a combined $60.3M — up 0.05% from $60.2M a quarter earlier.

Buyers outnumbered sellers: 10 funds opened new ARCT positions and 3 closed out — a net gain of 7 holders — while 11 added to existing stakes and 6 trimmed.

The largest buyer was J. Goldman & Co, opening a new position worth an estimated $2.26M. The largest seller was Verition Fund Management, cutting an estimated $3.44M.

  • 31 institutional investors held Arcturus Therapeutics (ARCT) as of Q2 2014, up from 24 in Q1 2014.
  • Funds reported $60.3M of Arcturus Therapeutics stock for Q2 2014, up 0.05% quarter-over-quarter.
  • 10 funds opened new Arcturus Therapeutics positions in Q2 2014 and 3 closed out, a net change of +7 holders.
  • The largest Arcturus Therapeutics buyer in Q2 2014 was J. Goldman & Co, an estimated $2.26M added.
  • The largest Arcturus Therapeutics seller in Q2 2014 was Verition Fund Management, an estimated $3.44M sold.

Based on aggregated 13F filings for Q2 2014.